# Accurate and cost-effective detection of mutagenicity and mutagenic exposure

> **NIH NIH R43** · MUTAGENTECH, INC. · 2024 · $275,763

## Abstract

ABSTRACT
Mutations in the genome of somatic cells in multicellular organisms result from DNA repair or replication errors,
causing cancer and other age-related diseases. As DNA mutations are irreversible, they represent the critical
molecular endpoint of the interaction between DNA damage and genome integrity maintenance mechanisms.
Thus, quantifying diverse mutation types in cells and tissues is essential in genetic toxicology for assessing
genetic risk associated with human exposure to environmental and anthropogenic agents. Current techniques
face challenges due to low mutation abundance and indistinguishability from sequencing errors. We propose
optimizing and validating Single Molecule Mutation Sequencing (SMM-seq), a novel approach for accurate,
cost-effective assessment of somatic mutations in normal cells and tissues. SMM-seq detects single-nucleotide
variants, small insertions and deletions, and structural variants, providing a comprehensive tool for somatic
mutational burden assessment. Our research has two specific aims: 1) optimize and validate an integrated
SMM-seq assay for measuring the mutational landscape of normal cells, focusing on protocol consolidation,
automation, and precision and recall evaluation; and 2) assess the mutagenicity of known genotoxic agents on
human primary cells. In this Phase 1, we will establish the technical merit and feasibility of SMM-seq and
develop a prototype platform, and scale up and expand applications in subsequent phases. The resulting
diagnostic product will address a market gap by providing a practical analytical tool for integrated genetic
toxicity/mutagenicity testing and monitoring human exposure to mutagenic agents, supporting the launch of a
successful business venture.

## Key facts

- **NIH application ID:** 10830629
- **Project number:** 1R43ES036101-01
- **Recipient organization:** MUTAGENTECH, INC.
- **Principal Investigator:** Alexander Y. Maslov
- **Activity code:** R43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $275,763
- **Award type:** 1
- **Project period:** 2024-02-06 → 2025-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10830629

## Citation

> US National Institutes of Health, RePORTER application 10830629, Accurate and cost-effective detection of mutagenicity and mutagenic exposure (1R43ES036101-01). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10830629. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*